1. No category

75th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GLANCE
FRIDAY, JUNE 5, 2015:
6:30 p.m. – 9:30 p.m.
6:30 p.m. – 7:00 p.m. – Registration and Dinner
7:00 p.m. – 9:30 p.m. – Educational Program
Nuevas Insulinas y el Cambiante Panorama en el Cuidado de la Diabetes Tipo 2
(Presentado en Español)
Jointly sponsored by University of Texas Southwestern Medical Center and Worldwide Initiative for
Diabetes Education
Supported by an unrestricted educational grant from Novo Nordisk
Contacts:
Mark Vinciguerra, University of Texas Southwestern Medical Center
Phone/Email: 214-648-4852; Mark.Vinciguerra@UTSouthwestern.edu
Jane Savio, Worldwide Initiative for Diabetes Education
Phone/Email: 212-614-4337; Jane.Savio@worldwidediabetes.org
Location: Westin Boston Waterfront, Harbor Ballroom
Este simposio se enfocará en nuevas insulinas y nuevas tendencias en terapias de insulina, como es que
están redefiniendo el cuidado de la diabetes tipo 2 hoy en día y que esperanza están aportando para
hacer frente a la creciente demanda mundial debido al crecimiento de la diabetes y sus complicaciones.
6:30 p.m. – 9:30 p.m.
Novel Mechanisms and Advancing Therapeutic Paradigms for Optimizing LDL-Focused Management
and Cardioprotection in the Diabetic Patient
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi US-Regeneron
Contact: Milo Falcon
Phone: 888-977-1625
Location: Boston Marriott Copley Place, Grand Ballroom G-K
This symposium will discuss novel mechanisms and advancing therapeutic paradigms for optimizing LDLfocused management and cardioprotection in diabetic patients. It will focus on clinical trials,
mechanisms of atherosclerotic heart disease, novel LDL targets and therapies, and new translational
dimensions of applying advances in LDL reduction to the diabetes population.
SATURDAY, JUNE 6, 2015:
5:30 a.m.- 7:30 a.m.
5:30 a.m. – 6:00 a.m. – Breakfast
6:00 a.m. – 7:30 a.m. – Symposium
Clinical Issues in Type 2 Diabetes: Discussions and Debates Around GLP-1 Receptor Agonists
Updated 3/31/15 (for website)
Jointly provided by Clinical and Patient Educators Association and Integritas Communications
Supported by an educational grant from AstraZeneca
Contact: Barbara Jean Wynne
Phone: 201-535-4941
Location: Boston Marriott Copley Place, Grand Ballroom G-K
During this Clinical Issues™ program, experts in diabetes research and patient care will discuss and
debate a set of topics related to the potential clinical roles of GLP-1 receptor agonists. Throughout the
program, the faculty panel will provide practical consensus recommendations for areas in which
published evidence for GLP-1 receptor agonists has only recently emerged.
6:15 p.m. - 8:45 p.m.
6:15 p.m. – 7:00 p.m. – Registration
7:00 p.m. – 8:45 p.m. – Symposium
Seeing into the Future: Preventing, Diagnosing and Treating Diabetic Eye Disease
Sponsored by FocusCME
Supported by an educational grant from Regeneron Pharmaceuticals
Contact: Steven Scrivner
Phone: 859-948-0099
Location: Boston Marriott Copley Place, Grand Ballroom G-K
The goal of this activity is to reinforce traditional strategies and educate clinicians about new strategies
for managing eye health of patients with diabetes. An emphasis will be placed on the need for enhanced
communication between the eye care specialist, as well as a general understanding of the therapeutic
options available to aid in patient counseling.
6:15 p.m. - 9:00 p.m.
6:15 p.m. – 7:00 p.m. – Registration and Dinner
7:00 p.m. – 9:00 p.m. – Scientific Program
Patient-Centered Management of Type 2 Diabetes: A Focus on the Newer Antihyperglycemic Agents
Sponsored by Institute for Medical and Nursing Education, Inc.
Supported by an educational grant from AstraZeneca
Contact: Katie Fidanza
Phone: 404-443-1511
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
Current type 2 diabetes mellitus (T2DM) treatment guidelines emphasize individualized glycemic targets
and patient-centered treatment regimens. This highly interactive symposium will use standardized
patients to demonstrate effective techniques for providing patient-centered T2DM care using newer
classes of antihyperglycemic agents, including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1
receptor agonists, and sodium-glucose cotransporter 2 inhibitors. Practical, evidence-based
recommendations for individualizing therapy in T2DM patients with common comorbidities—
cardiovascular disease, chronic kidney disease, or obesity will be featured.
Updated 3/31/15 (for website)
6:15 p.m. - 9:15 p.m.
Eighth Annual Gerald J. Friedman Fellows Symposium "Nutrition, Diabetes and Human Health"
Sponsored by Tufts University, Friedman School of Nutrition Science and Policy
Supported by an educational grant from Gerald J. and Dorothy R. Friedman New York Foundation for
Medical Research
Contact: Leonid Poretsky, MD
Phone: 212-434-3662
Location: Westin Boston Waterfront, Harbor Ballroom
Since 2000 the Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research has
supported the work of 41 research fellows (for details see http://friedmanfellows.com/fellows/). The
8th Annual Friedman Fellows Symposium will have the following program: Oral and poster presentation;
A debate titled, “Obesity, Nature and Nurture” with plenary speakers Drs. Jeffrey Flier and Terry
Maratos-Flier of Harvard Medical School. Friedman Fellows will address a variety of issues related to
nutrition, diabetes and human health.
6:15 p.m. - 9:15 p.m.
Type 2 DM- Emerging Therapeutic Trends in OADs and Insulin Combinations
Sponsored by Scripps Health
Supported by an educational grant from Sanofi Aventis
Contact: Athena Philis-Tsimikas, MD
Phone: 858-678-7077
Location: Boston Marriott Copley Place, Grand Ballroom A-F
This symposium will highlight the latest concepts in the treatment of diabetes and will focus on:
• Unmet needs and treatment patterns of patients with type 2 diabetes on basal insulin
• Knowledge of new basal insulins in development
• Strategies to mitigate identified barriers to basal insulin-mediated glucose control
Symposium to cover:
• Latest recommendations for advancing diabetes care
o Review 2015 Standards of Care
o How do new therapeutic classes fit into the treatment regimen
o Interactive case discussions with audience response technology
• Emerging basal insulins in development
o Review current unmet needs
o Overview of agents in development
o Recent clinical trial results
• Strategies for advancing basal insulin therapy and addressing patient barriers
o Combination therapies to optimize control
o Interactive case discussions with audience response technology
Updated 3/31/15 (for website)
SUNDAY, JUNE 7, 2015:
5:00 a.m.- 7:45 a.m.
5:00 a.m. – 5:30 a.m. – Registration and Breakfast
5:30 a.m. – 7:45 a.m. – CME Symposium
Complementary Treatments to Enhance Insulin Efficacy: Theory and Strategies
Sponsored by Joslin Diabetes Center
Supported by an educational grant from sanofi-aventis US
Contact: Sherlyn B. Celone
Phone: 203-451-3164
Location: Westin Boston Waterfront, Harbor Ballroom
Today’s selection of antidiabetes medications improves efficacy and individualization. Yet our nonspecialist colleagues often find the options, combinations and barriers to therapeutic advancement
daunting. This program will address combined GLP-1 RA/basal insulin, and help empower specialists to
be more effective resources for primary care in achieving optimal glycemic control.
6:45 p.m. - 9:00 p.m.
6:45 p.m. – 7:30 p.m. – Dinner
7:30 p.m. – 9:00 p.m. – Symposium
Addressing Postprandial Glucose Excursions in T2DM with Inhaled Insulin
Sponsored by MediKinetics
Supported by an educational grant from Sanofi
Contact: Katie McGowan
Phone: 858-717-2940
Location: Westin Boston Waterfront, Harbor Ballroom
A recently approved inhaled insulin provides a convenient prandial option that does not require multiple
daily injections and more closely mimics prandial insulin secretions in healthy adults. The drug-device
combination is a dry formulation of human insulin delivered through a small inhaler that is administered
at the start of a meal. Join our symposium to learn more!
6:45 p.m. - 9:15 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:15 p.m. – CME-certified Activity
Avoiding “Loss of Chance”….Improving the Screening, Treatment and Referral of Patients with
Diabetic Retinopathy
Provided by Vindico Medical Education
Supported by an educational grant from Genentech, Inc.
Contact: Emily Scully
Phone: 856-994-9400
Email: escully@vindicocme.com
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
Updated 3/31/15 (for website)
Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in
the United States, in part because many patients are not identified as needing therapy. In addition to
counseling patients on the impact glucose control have on maintaining vision, clinicians should
emphasize the need for vision screening among patients with diabetes. Early detection offers the best
long-term visual outcomes, and is even more important with a new treatment approved for the
management of diabetic retinopathy and another being considered. In this activity, leading
endocrinologists and retina specialists will discuss preventive measures that clinicians can take to delay
or prevent vision loss in patients with diabetes and review the latest data on treatment options for
patients with diabetic eye disease.
7:00 p.m. - 9:30 p.m.
7:00 p.m. – 7:30 p.m. – Registration and Buffet Dinner
7:30 p.m. – 9:30 p.m. – Activity
The Evolution of Insulin: Applying the Fundamentals of Insulin Physiology to Build a Better Insulin
Sponsored by Creative Educational Concepts, Inc.
Supported by an educational grant from Lilly
Contact: Ashley C. Lilly
Phone: 859-260-1717 x117
Location: Boston Marriott Copley Place, Grand Ballroom G-K
The goal of this activity is to explore key differences between exogenous insulin administration and
normal endogenous insulin physiology to better understand the limitations of current insulin
preparations and the need to “build a better insulin.” Expert faculty will examine the metabolic
abnormalities and adverse effects associated with exogenous insulin administration resulting from overinsulinization of the peripheral tissues and loss of the normal hepatic to peripheral insulin gradient.
Attendees will gain an appreciation of the “evolution” of insulin preparations from discovery to their
future in modern medicine.
MONDAY, JUNE 8, 2015:
6:45 p.m. – 9:15 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:15 p.m. – CME-certified Activity
Combining Therapeutic Advances with Patient Engagement to Optimize Treatment for Patients with
Obesity
Provided by Vindico Medical Education
Supported by an educational grant from Novo Nordisk
Contact: Emily Scully
Phone: 856-994-9400
Email: escully@vindicocme.com
Location: Westin Boston Waterfront, Harbor Ballroom
Updated 3/31/15 (for website)
Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. In
addition, various medical societies have issued recommendations to guide the use of available
treatments for obesity. Obesity is a particularly challenging condition in terms of motivating patients to
adhere to behavioral and pharmacologic regimens that in many cases require a lifetime commitment. In
the last few years, there has been considerable development in pharmacologic options for managing
obesity, requiring clinicians to have a thorough understanding of the efficacy and risks associated with
each agent in order to help patients determine the most appropriate medication. In this highly
interactive program, leading specialists will summarize the latest guidelines for the management of
obesity, discuss how to encourage adherence among patients and review all pharmacologic options for
the management of obesity in case presentations that allow learners to manage patients along with the
panel.
6:45 p.m. - 9:30 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:30 p.m. – Symposium
Cardiovascular Outcomes Associated with Antihyperglycemic Agents: New Data, Clinical Application,
and Key Takeaways for Your Type 2 Diabetes Practice
Sponsored by Medscape Education
Supported by an educational grant from Merck
Contact: Kelly Hanley
Phone: 973-670-1861
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
This live event will address the following learning objectives:
• Identify the rationale for cardiovascular (CV) outcomes trials in patients with type 2 diabetes
• Review clinical data related to antihyperglycemic agents and CV outcomes
• Assess clinical and practical implications of CV outcomes with antihyperglycemic agents trials
Updated 3/31/15 (for website)